DNA vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial distress and operational deterioration. Despite a strong current ratio of 4.92 providing a short-term liquidity buffer, the company is facing a systemic collapse in growth with YoY revenue declining by 23.80%. Massive negative operating margins (-209.74%) and a catastrophic 5-year price decline of 98.1% suggest a failing business model. The combination of shrinking top-line revenue and bearish insider selling confirms a high-risk profile.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
DNA vs LLY: Head-to-Head Comparison
This page compares Ginkgo Bioworks Holdings, Inc. (DNA) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.